In this video, Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, gives an overview of what to look forward to at EHA 2023 in the field of multiple myeloma, highlighting the exciting data emerging from the CARTITUDE-4 trial (NCT04181827), novel combinations and trials with bispecific antibodies, and the possibility of using measurable residual disease (MRD) to optimize therapy. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.